Biblio Discovery — Demo Discovery Service

11 hasil untuk "Mat Makowski"

Menampilkan 1–11 · 0,33 detik · RSS

  1. Artikel Jurnal

    Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 studyResearch in context

    Fadima Cheick Haidara; Milagritos D. Tapia; Fatoumata Diallo dkk.

    EClinicalMedicine, Vol. 71 · 2024 · Inggris · DOAJ Scopus

    Summary: Background: While maternal pertussis vaccination is a strategy to reduce infant morbidity, safety and immunogenicity data are limited in sub-Saharan Africa. We aimed to evaluate the safety of a single dose of tetanus, diphtheria and acellular pertussis vaccine (Tdap) vaccine compared to…

  2. Artikel Jurnal

    Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

    Felicia Scaggs Huang; David I. Bernstein; Karen S. Slobod dkk.

    Human Vaccines & Immunotherapeutics, Vol. 17 No. 2 · 2021 · Inggris · DOAJ Scopus

    SeVRSV is a replication-competent Sendai virus (SeV)-based vaccine carrying the respiratory syncytial virus (RSV) fusion protein (F) gene. Unmanipulated, non-recombinant SeV is a murine parainfluenza virus type 1 (PIV-1) and serves as a Jennerian vaccine for human PIV-1 (hPIV-1). SeV protects…

  3. Artikel Jurnal

    Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

    Nicole A. Doria‐Rose; Mehul S. Suthar; Mat Makowski dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...

  4. Artikel Jurnal

    Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

    Alicia T. Widge; Nadine Rouphael; Lisa A. Jackson dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...

  5. Artikel Jurnal

    An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson; Evan J. Anderson; Nadine Rouphael dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. METHODS: We…

  6. Artikel Jurnal

    Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

    Evan J. Anderson; Nadine Rouphael; Alicia T. Widge dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age…

  7. Artikel Jurnal Teks lengkap

    Remdesivir for the Treatment of Covid-19 — Final Report

    John H. Beigel; Kay M Tomashek; Lori Elizabeth Dodd dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who…

  8. Artikel Jurnal Teks lengkap

    Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

    Amarendra Pegu; Sarah E. O’Connell; Stephen D. Schmidt dkk.

    Science · 2021 · Inggris · OpenAlex Scopus

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526…

  9. Artikel Jurnal

    Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial

    Polina Shindiapina; Maciej Pietrzak; Michal Seweryn dkk.

    Frontiers in Immunology, Vol. 12 · 2021 · Inggris · DOAJ Scopus

    We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days…

  10. Artikel Jurnal

    Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

    Bo Zhang; Youyi Fong; Lauren Dang dkk.

    Nature Communications, Vol. 16 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance. For 985 recipients of an mRNA…

  11. Artikel Jurnal

    Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

    Ilias I. Siempos; Andre C. Kalil; Drifa Belhadi dkk.

    EClinicalMedicine, Vol. 69 · 2024 · Inggris · DOAJ Scopus

    Summary: Background: Although immunomodulators have established benefit against the new coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve outcomes without increasing the risk of secondary infections in the specific subgroup of previously immunocompromised…